ALTERITY THERAPEUTICS LTD

FY: Jun 30 2026

FY: Jun 30 2025

FY: Jun 30 2024

FY: Jun 30 2023

FY: Jun 30 2022

FY: Jun 30 2021

FY: Jun 30 2020

FY: Jun 30 2019

FY: Jun 30 2018

FY: Jun 30 2017

FY: Jun 30 2016

FY: Jun 30 2015

FY: Jun 30 2014

FY: Oct 31 2014

FY: Jun 30 2013

FY: Jun 30 2012

FY: Jun 30 2011

FY: Jun 30 2010

FY: Jun 30 2009

FY: Jun 30 2008

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans

Prospectus Supplement for Primary Offering

Notice of Effectiveness

Registration statement for securities of certain foreign private issuers

Notice of Effectiveness

Prospectus Supplement for Primary Offering

Registration statement for securities of certain foreign private issuers

Prospectus Supplement for Primary Offering

Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans

Notice of Effectiveness

Prospectus Supplement for Primary Offering

Registration statement for securities of certain foreign private issuers

Notice of Effectiveness

Registration statement for securities of certain foreign private issuers

Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans

Prospectus Supplement for Primary Offering

Notice of Effectiveness

Registration statement for securities of certain foreign private issuers

Prospectus Supplement for Primary Offering

Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans

Stamler David Allen

Marks Peter Ashley

Babarczy Julian Michael

Gozlan Lawrence Bernard

Cunningham Ann Michelle

Stamler David Allen

Marks Peter Ashley

Babarczy Julian Michael

Gozlan Lawrence Bernard

Macnish Niven Abby Sarah

JPMORGAN CHASE & CO

JPMORGAN CHASE & CO

none

none

none

none

none

none

none

Life Biosciences LLC

Correspondence with the SEC

Letter from the SEC

Correspondence with the SEC

Letter from the SEC

Correspondence with the SEC

Letter from the SEC

Correspondence with the SEC

Letter from the SEC

Correspondence with the SEC

Letter from the SEC

Correspondence with the SEC

Letter from the SEC

Letter from the SEC

Correspondence with the SEC

Correspondence with the SEC

Letter from the SEC

Letter from the SEC

Correspondence with the SEC

Letter from the SEC

Correspondence with the SEC